Carolinas HealthCare System

Research and Clinical Trials

Soft Tissue 

Brief Description PrincipalĀ Investigator
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow samples from patients with soft tissue sarcoma that will be tested in the laboratory. Kaplan, Joel Adam 
The purpose of this study is to evaluate the factors currently used for risk-group assignment (DNA content, MYCN copy number, and tumor histology) in patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Kaplan, Joel Adam 
The first part of the study will determine the feasibility of adding pazopanib in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk (Non-Rhabdomyosarcoma Soft Tissue Sarcomas) NRSTS.

The second part of the study will compare the rates of response of (1) preoperative pazopanib plus chemoradiation versus preoperative chemoradiation alone for potentially resectable > 5 cm, Grade 3 intermediate to high risk ch
Kaplan, Joel Adam 
The primary objective of this study is to determine the efficacy of administration of aldoxorubicin compared to investigator's choice of treatment in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have relapsed or were refractory to prior non-adjuvant chemotherapy, as measured by progression-free survival (PFS). Livingston, Michael Balfour 
To evaluate the preventative activity of DFMO as a single agent in patients that are in remission based on: Event Free Survival (EFS). Oesterheld, Javier E 
Primary Objectives and Endpoints
1.1.1 To evaluate the safety and tolerability of ODSH in pediatric patients receiving ?ICE? (Ifosfamide mixed with Mesna, Carboplatin and Etoposide) chemotherapy.

1.1.2 To evaluate preliminary evidence of an effect of ODSH on time to platelet recovery, defined as when the platelet count remained > 100,000 after nadir for two consecutive days in the absence of a prior platelet transfusion within the previous 48 hours in pediatric patients receiving ?ICE? c
Oesterheld, Javier E 
To compare the progression-free survival (PFS) of eligible subjects treated with regorafenib or placebo according to modified RECIST version 1.1. Livingston, Michael Balfour 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.